Six- and twelve-month clinical outcomes after implantation of prokinetic BMS in patients with acute coronary syndrome.
To evaluate the Prokinetic bare metal stent implanted in patients presenting with acute coronary syndrome (ACS). We retrospectively studied ACS patients who underwent percutaneous coronary intervention (PCI) with a Prokinetic stent implantation. Excluded were patients presenting with cardiogenic shock, undergoing PCI to left main coronary artery (LM), or having implantation of additional stents other than Prokinetic. Six and 12 months clinical follow-up was obtained by phone. A total of 140 Prokinetic stents were implanted in 117 patients (age 64+/-13.0 years, 78% men). Thirty two percent of the patients had unstable angina, 36% had non ST-elevation myocardial infarction (NSTEMI) and 33% had ST-elevation myocardial infarction (STEMI). Forty two percent of lesions were categorized as B2 and 21% as C type. Procedural success was achieved in 99.1% of lesions. Clinical success was achieved in 97.4% of patients. Major adverse cardiac events (MACE) rate was 8.5% and 11.1% at 6 and 12 months follow-up, respectively. The incidence of cardiac death, MI and TLR was 2.6%, 3.4% and 2.6%, respectively at 6 months, and 4.3%, 4.3%, 2.6% respectively at 12 months. Clinical outcomes at 6 and 12 months after Prokinetic stent implantation are excellent and may be attributable to its unique combination of composition, design and coating.